Importantly, beyond the HR and/or HER2 status detected in tissue, liquid biopsy provides a new concept to characterize and monitor the tumor genome and is increasingly being used as a tool to further guide clinical decision making [25, 29, 34, 35, 36]. This evidence concerns the gene ERBB2 and neoplasm.